Probucol delays progression of diabetic nephropathy
Probucol delays progression of diabetic nephropathy
复制标题
DOI：
10.1016/j.diabres.2005.05.012
复制
发表时间：
2006-02-01
影响因子：
5.1
通讯作者：
Shirai, K
中科院分区：
文献类型：
--
作者：
Endo, K;Miyashita, Y;Shirai, K
普罗布考具有抗氧化和降低胆固醇的作用。本研究探讨普罗布考对糖尿病肾病进展的影响。我们对102例有临床白蛋白尿（尿白蛋白排泄> 300 mg/g Cr）的2型糖尿病患者进行了一项随机、开放试验。51名患者被分配到普罗布考治疗（500毫克/天）和51没有普罗布考治疗。在所有患者中，40例基线时血清肌酐>= 2 mg/dl的患者被定义为晚期病例。所有患者均随访最长3年。HbA 1c水平在两组之间没有差异。普罗布考组高密度脂蛋白胆固醇显著降低。非普罗布考组尿蛋白增加（g/天/月）显著大于普罗布考组。23例患者开始血液透析（普罗布考组10例，非普罗布考组13例）。普罗布考组开始血液透析的平均间隔（20.7 ± 8.2个月）明显长于非普罗布考组（11.3 ± 7.4个月）。普罗布考组能明显抑制晚期患者血肌酐和尿蛋白的升高。在晚期患者中，普罗布考组的免透析率明显高于非普罗布考组。这些结果表明，普罗布考可以抑制糖尿病肾病的进展。(c)2005爱思唯尔爱尔兰有限公司保留所有权利。
Probucol has antioxidant and cholesterol-lowering effects. This study examined the effect of probucol on progression of diabetic nephropathy. We performed a randomized, open trial on 102 type 2 diabetes patients with clinical albuminuria (urinary albumin excretion > 300 mg/g Cr). Fifty-one patients were assigned to probucol treatment (500 mg/day) and 51 to no probucol treatment. Among all patients, 40 who had serum creatinine >= 2 mg/dl at baseline were defined as advanced cases. All patients were followed for a maximum 3 years. HbA1c levels were not different between two groups. High-density lipoprotein cholesterol decreased significantly in probucol group. Increase in urinary protein (g/day/month) was significantly greater in nonprobucol than in probucol group. Hemodialysis was initiated in 23 patients (10 in probucol group and 13 in non-probucol group). The mean interval to initiation of hemodialysis was significantly longer in probucol group (20.7 +/- 8.2 months) than in nonprobucol group (11.3 +/- 7.4 months). In advanced cases, increases of both serum creatinine and urinary protein were significantly suppressed in probucol group. In advanced cases, the hemodialysis-free rate was significantly higher in probucol group than in non-probucol group. These results suggest that probucol may suppress the progression of diabetic nephropathy. (c) 2005 Elsevier Ireland Ltd. All rights reserved.